Coloplast A/S (OTCMKTS:CLPBY) Short Interest Update

Coloplast A/S (OTCMKTS:CLPBYGet Rating) saw a large growth in short interest in the month of December. As of December 30th, there was short interest totalling 31,200 shares, a growth of 10,300.0% from the December 15th total of 300 shares. Based on an average daily trading volume, of 179,000 shares, the short-interest ratio is currently 0.2 days.

Coloplast A/S Stock Performance

Shares of CLPBY stock opened at $12.33 on Wednesday. Coloplast A/S has a 12 month low of $9.58 and a 12 month high of $16.00. The company’s fifty day simple moving average is $12.01 and its 200-day simple moving average is $11.46. The firm has a market cap of $26.63 billion, a PE ratio of 41.10 and a beta of 0.28. The company has a quick ratio of 0.90, a current ratio of 1.29 and a debt-to-equity ratio of 0.02.

Coloplast A/S Increases Dividend

The firm also recently disclosed a dividend, which was paid on Friday, December 16th. Stockholders of record on Monday, December 5th were paid a dividend of $0.1349 per share. This represents a dividend yield of 1.53%. This is an increase from Coloplast A/S’s previous dividend of $0.05. The ex-dividend date was Friday, December 2nd. Coloplast A/S’s dividend payout ratio is currently 73.33%.

Wall Street Analysts Forecast Growth

CLPBY has been the topic of several research analyst reports. UBS Group dropped their price objective on Coloplast A/S from 878.00 to 840.00 in a research note on Tuesday, November 8th. Credit Suisse Group lowered their target price on Coloplast A/S from 1,100.00 to 1,045.00 in a research note on Wednesday, November 9th. Barclays cut their price target on shares of Coloplast A/S from 835.00 to 815.00 and set an “underweight” rating on the stock in a research note on Tuesday, January 10th. Jefferies Financial Group downgraded shares of Coloplast A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, September 20th. Finally, Morgan Stanley started coverage on shares of Coloplast A/S in a research note on Tuesday, October 18th. They issued an “overweight” rating for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $920.00.

About Coloplast A/S

(Get Rating)

Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.

See Also

Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with's FREE daily email newsletter.